|
NORD Corporate Council Meeting Presentations
May 21, 2007 - Capital Hilton Hotel, Washington DC
Discussion: Follow-on Biologics and A Washington DC Update
Follow-on Biologics: A Patient Advocate's View
Shawn O'Neal, Associate
Vice President, Federal Government Relations,
National Multiple Sclerosis Society
Follow-on Biologics: Coalition View
(no presentation available)
William B. Schultz
Zuckerman Spaeder LLP
Follow-on Biologics: An Industry View
Audrey Phillips, PhD.
Executive Director,
BioPharmaceutical Public
Policy Planning, Johnson & Johnson
Bio-Similars: A European Approach to Follow-on Biologics and Recent Drug Regulatory Development in EU
Yann Le Cam
Chief Executive Officer
European Organisation for Rare Diseases
(EURORDIS)
To Be or Not to Be, Follow-on Biologics
Diane Dorman
Vice President Public Policy
NORD
FDA Office of Orphan Product Development: An Update
Debra Y. Lewis OD
Acting Director
Office of Orphan Product Development, FDA
NIH Office of Rare Diseases: An Update
Stephen Groft, PharmD.
Director,
Office of Rare Diseases, NIH
|
Read about events on Capitol Hill, funding for rare-disease research, and other topics of interest from NORD's office in Washington, DC.